Engleski Frequency of vascular risk factors and the impact of their treatment on the outcome of acute ischemic stroke in patients treated with recanalization therapy
Abstract
ABSTRACT:
Introduction: Stoke is one of the leading causes of death and longterm disability worldwide. Timely diagnosis and control of vascular risk factors is a priority for stroke prevention.
Material and methods :A retrospective analysis of data on stroke patients treated with recanalization therapy in a one-year period was performed. The analysis contained the characteristics of the study population, risk factors and comorbidities and the therapy used in stroke primary prevention. Symptomatic intracerebral haemorrhage (sICH) was defined according to ECASS-2 criteria. Patients' functional outcome after three months was assessed by using a modified Rankin scale score (mRS).
Results: The study included a total of 117 stroke patients of whom 70 (60%) were small. The average age of the study population was 65 years (64.6 ± 14), with a baseline NIHSS score of 12 (12 ± 6.7). The most often present risk factors were arterial hypertension and hypercholesterolemia. The most commonly used drugs in primary prevention were antihypertensives and antithrombotic therapy. Afterwards, patients were divided into two groups (those with previous antithrombotic (AT) therapy and those without). Patients who were not on previous AT therapy were: more often male, aged 45-75 years or younger than 45 years, less often had previous AF, hypercholesterolemia and previous stroke. They also had a trend of initially lower NIHSS score. There were no statistical differences in the occurence of sICH between the two groups.
Conclusion: The identification of stroke risk factors within all age groups and their treatment is of great importance in primary prevention of stroke. A previous use of antithrombotic therapy does not increase the likelihood of sICH occurence in stroke patients treated with recanalization therapy.
References
- Kostić S. Vladimir plays the author, Neurology for medical students; Belgrade: Faculty of Medicine, University of Belgrade; 2007; 237-263
- Patel RA, White CJ. Acute ischemic stroke treatment: State of the art.VascMed.2011; 16 (1): 19–28.
- Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367 (9524): 1747-1757.
- Boehme AK, Esenwa C, Elkind MS. Stroke Risk Factors, Genetics, and Prevention. Circ Res. 2017; 120 (3): 472-495.
- Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008; 7 (10): 915-926.
- Furie K. Epidemiology and Primary Prevention of Stroke. Continuum (MinneapMinn). 2020 Apr; 26 (2): 260-267.
- Caprio FZ, Sorond FA. Cerebrovascular Disease: Primary and Secondary Stroke Prevention. Med Clin North Am. 2019; 103 (2): 295-308.
- Pandian JD, Gall SL, Kate MP, Silva GS, Akinyemi RO, Ovbiagele BI, et. Prevention of stroke: a global perspective. Lancet. 2018; 392 (10154): 1269-1278.
- Lees, KR, Bluhmki, E, von Kummer, R. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010; 375 (9727): 1695–1703.
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association / American Stroke Association. Stroke. 2019; 50 (12).
- Turc G, Bhogal P, Fischer U, Khatri P, Lobotesis K, Mazighi M, et al. European Stroke Organization (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute IschaemicStrokeEndorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J. 2019; 4 (1): 6-12.
- Liebeskind DS, Bracard S, Guillemin F, Jahan R, Jovin TG, Majoie CB, et al. eTICI reperfusion: defining success in endovascular stroke therapy. J NeuroIntervent Surg. 2019; 11 (5): 433–8
- Rabinstein AA. Update on Treatment of Acute Ischemic Stroke. Continuum (MinneapMinn). 2020; 26 (2): 268-286.
- Kwah LK, Diong J. National Institutes of Health Stroke Scale (NIHSS). J Physiother. 2014; 60 (1): 61.
- Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association / American Stroke Association. Stroke. 2014; 45 (12): 3754-832.
- Sarikaya H, Ferro J, Arnold M. Stroke prevention - medical and lifestyle measures. Eur Neurol. 2015; 73 (3-4): 150-7.
- Endres M. Statins and stroke. J Cereb Blood Flow Metab. 2005; 25 (9): 1093-110.
- Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009; 40 (1): 235-40.
- Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med. 2003; 163 (13): 1580-6.
- McBride D, Bruggenjurgen B, Roll S et al. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis 2007; 24: 65-72.
- Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol. 2021; 18 (4): 276-290.
- Okşul M, ZiyaŞener Y, C.öteli C. CHADS-VASc Score in STEMI Patients: Should We Use It Really? ActaCardiol Sin. 2019; 35 (1): 89.
- Yoshizawa R, Komatsu T, Kunugita F, Ozawa M, Ohwada S, Satoh Y, et al. Comparison of the CHADS2, CHA2DS2-VASc and R2CHADS2 Scores in Japanese Patients with Non-valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulation Therapy. Intern Med. 2017; 56 (21): 2827-2836.
- Shah RS, Cole JW. Smoking and stroke: the more you smoke the more you stroke. Expert Rev CardiovascTher. 2010; 8 (7): 917-32.
- Diener HC, Hankey GJ. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. J Am CollCardiol. 2020; 75 (15): 1804-1818.
- Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2 Suppl).
- Sherman DG. Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step? Cerebrovasc Dis. 2004; 17Suppl 1: 138-43.
- Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008; 133.
- Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012; 157 (11): 796-807.